We are pleased to announce that the acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners has been completed. Read the Press Release

All Resources

A Customer-Centric Approach to Cell & Gene Therapy Manufacturing

October 13, 2021

Learn more about the drivers motivating Avid Bio’s entrance into the viral vector space, and the unique and differentiating value the company can offer cell and gene therapy developers.

All Resources

A Customer-Centric Approach to Cell & Gene Therapy Manufacturing

Sign up for Avid emails.

Follow Us:

Get the latest from Avid.

Follow Us:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content: